Navigation Links
New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment

FAS20013, a tuberculosis drug, currently in the experimental phase has offered hope in the treatment of multiple drug resistant and latent infections as well. The mechanism of action of the new drug is different // than those used for conventional treatment.

The drug targets slow growing mycobacteria involved in the disease process and induces selective killing of the same. The other drugs target a broad spectrum of non-pathogenic microorganisms that enables development of drug resistance. Nearly all isolates have been shown to be susceptible to the compound and no resistance has been observed.

The compound is the first ever known to combat latent infection. Following infection, some patients go into a latent phase where no symptoms are seen. Such patients are not capable of infecting others, as they do not have an active infection. However, they can develop active infection at any time. Worldwide, more than 2 billion people have this latent form of the disease.

Furthermore, the drug action is precipitated in just 4 hours while Rifampicin or Isoniazid needs 12 to 14 hours to destroy the pathogen. The pharmaceutical company FASgen, Inc., is working towards marketing the novel drug for commercial use.

Overcoming multiple drug resistance in tuberculosis represents a significant challenge in the successful treatment of tuberculosis. It is associated with a fatality rate ranging from 20 to 80%. The presence of an uncontrollable active infection and failure to respond to any therapy are strong indications for isolation of the patient to prevent the emergence of drug resistant strains in the population. In worst cases, it may be even required to perform surgical resection of a part of the lung. The cost associated with such a treatment can be as high as $250,000.

The drug is currently being investigated in laboratory animals to estimate the beneficial and toxic effects. An application would soon be submitted to th e Food and Drug Administration (FDA) regarding proceeding with clinical trials of the investigational new drug (IND). If promising results are obtained, we could soon have an anti-tuberculous drug for treatment of MDR-TB.


'"/>




Related medicine news :

1. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
2. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
3. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
4. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
5. Raw Vegan Diet Promises Lightweight, Healthy Bones
6. Stem Cell Transplantation Promises Cure for Type 2 Diabetes
7. Health Minister Promises Strict Quality Control On Herbal Medicines
8. Anti-Cancer Treatment Promises Hope in Bird Flu Treatment
9. Nanotechnology Promises Huge Medical Benefits
10. Health Minister Promises New Benchmark for Wait Times
11. Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
Breaking Medicine Technology: